---
category: listing
circular_id: bb9a40ca1eea32a9
date: '2025-11-20'
description: Beta Drugs Limited's equity shares are being listed on the NSE Main Board
  following migration from the SME Emerge platform, with shareholding pattern as of
  November 13, 2025.
draft: false
guid: https://nsearchives.nseindia.com/content/circulars/CML71376.zip
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Company migration from SME to Main Board is significant for existing
  shareholders and market participants, expanding trading opportunities and liquidity
pdf_url: https://nsearchives.nseindia.com/content/circulars/CML71376.zip
processing:
  attempts: 1
  content_hash: ed4053d3fd8a1ca9
  processed_at: '2025-11-20T13:00:54.316824'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-11-20T00:00:00+05:30'
rss_url: https://nsearchives.nseindia.com/content/circulars/CML71376.zip
severity: medium
source: nse
stocks:
- BETA
tags:
- capital-market
- equity
- listing
- main-board
- shareholding-pattern
- sme-migration
title: Listing of Equity Shares of Beta Drugs Limited on Capital Market Segment (Main
  Board) pursuant to migration from SME Emerge platform
---

## Summary

Beta Drugs Limited (NSE Symbol: BETA, ISIN: INE351Y01019) has migrated from the SME Emerge platform to the Capital Market Segment (Main Board) of NSE. The company filed its shareholding pattern under Regulation 31(1)(b) for the quarter ended November 13, 2025. The company is not a Public Sector Undertaking and has a total of 10,09,45,553 equity shares outstanding.

## Key Points

- Total shares outstanding: 10,09,45,553 equity shares
- Promoter and Promoter Group holding: 6,73,65,07 shares (66.73%)
- Public shareholder holding: 3,35,80,46 shares (33.27%)
- All shares are held in dematerialized form
- Quarter ended: November 13, 2025
- The company has no partly paid-up shares, convertible securities, warrants, or outstanding ESOPs
- No shares are locked-in, pledged, or under non-disposal undertaking
- No shares held under depository receipts
- No differential voting rights shares issued
- No significant beneficial owners reported

## Regulatory Changes

The migration from SME Emerge platform to Main Board brings Beta Drugs Limited under the full regulatory framework applicable to Main Board listed companies, including enhanced disclosure requirements and compliance obligations under SEBI LODR Regulations.

## Compliance Requirements

- Company must comply with Regulation 31(1)(b) of SEBI LODR Regulations for quarterly shareholding pattern filing
- Enhanced corporate governance norms applicable to Main Board listed entities
- Regular disclosures and filings as per Main Board listing requirements

## Important Dates

- Quarter Ended: November 13, 2025
- Shareholding Pattern Filing Date: As per Regulation 31(1)(b)

## Impact Assessment

The migration to Main Board is expected to enhance liquidity and visibility for Beta Drugs Limited's shares. With 66.73% promoter holding and 33.27% public float, the company meets Main Board listing requirements. The move provides access to a larger investor base and improved price discovery mechanisms. All shares being in dematerialized form facilitates seamless trading on the Main Board platform.